Cartesian Therapeutics (RNAC) Receivables - Other (2020 - 2024)

Cartesian Therapeutics (RNAC) has 5 years of Receivables - Other data on file, last reported at $980000.0 in Q3 2024.

• Receivables - Other for Q3 2024 came in at $980000.0, down 47.73% year-over-year; the trailing twelve-month figure through Sep 2024 was $980000.0 (down 47.73% YoY), and the FY2023 annual result was $3.0 million, down 5.72% from the prior year.
• Receivables - Other retreated to $980000.0 in Q3 2024 per RNAC's latest filing, from $3.5 million in the prior quarter.
• Over five years, Receivables - Other peaked at $3.5 million in Q2 2024 and troughed at $100000.0 in Q2 2021.
• A 5-year average of $1.7 million and a median of $1.5 million in 2020 frame the typical range for Receivables - Other.
• On a YoY basis, Receivables - Other climbed as much as 229.1% in 2024 and fell as far as 47.73% in 2024.
• A 5-year view of Receivables - Other shows it stood at $1.0 million in 2020, then changed by 0.0% to $1.0 million in 2021, then soared by 216.2% to $3.2 million in 2022, then decreased by 5.72% to $3.0 million in 2023, then sank by 67.13% to $980000.0 in 2024.
• Business Quant data shows RNAC's Receivables - Other at $980000.0 in Q3 2024, $3.5 million in Q2 2024, and $2.4 million in Q1 2024.